These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25793507)

  • 1. Protein-binding RNA aptamers affect molecular interactions distantly from their binding sites.
    Dupont DM; Thuesen CK; Bøtkjær KA; Behrens MA; Dam K; Sørensen HP; Pedersen JS; Ploug M; Jensen JK; Andreasen PA
    PLoS One; 2015; 10(3):e0119207. PubMed ID: 25793507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting tumor cell invasion and dissemination in vivo by an aptamer that inhibits urokinase-type plasminogen activator through a novel multifunctional mechanism.
    Botkjaer KA; Deryugina EI; Dupont DM; Gårdsvoll H; Bekes EM; Thuesen CK; Chen Z; Ploug M; Quigley JP; Andreasen PA
    Mol Cancer Res; 2012 Dec; 10(12):1532-43. PubMed ID: 23038812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum-stable RNA aptamers to urokinase-type plasminogen activator blocking receptor binding.
    Dupont DM; Madsen JB; Hartmann RK; Tavitian B; Ducongé F; Kjems J; Andreasen PA
    RNA; 2010 Dec; 16(12):2360-9. PubMed ID: 20962041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding areas of urokinase-type plasminogen activator-plasminogen activator inhibitor-1 complex for endocytosis receptors of the low-density lipoprotein receptor family, determined by site-directed mutagenesis.
    Skeldal S; Larsen JV; Pedersen KE; Petersen HH; Egelund R; Christensen A; Jensen JK; Gliemann J; Andreasen PA
    FEBS J; 2006 Nov; 273(22):5143-59. PubMed ID: 17042782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of the zymogen to urokinase-type plasminogen activator is associated with increased interdomain flexibility.
    Behrens MA; Botkjaer KA; Goswami S; Oliveira CL; Jensen JK; Schar CR; Declerck PJ; Peterson CB; Andreasen PA; Pedersen JS
    J Mol Biol; 2011 Aug; 411(2):417-29. PubMed ID: 21669207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNA aptamers as conformational probes and regulatory agents for plasminogen activator inhibitor-1.
    Madsen JB; Dupont DM; Andersen TB; Nielsen AF; Sang L; Brix DM; Jensen JK; Broos T; Hendrickx ML; Christensen A; Kjems J; Andreasen PA
    Biochemistry; 2010 May; 49(19):4103-15. PubMed ID: 20387790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of PAI-1 antiproteolytic activity against tPA by RNA aptamers.
    Damare J; Brandal S; Fortenberry YM
    Nucleic Acid Ther; 2014 Aug; 24(4):239-49. PubMed ID: 24922319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of Human Urokinase-Type Plasminogen Activator (uPA) Enzyme Activity and Receptor Binding by DNA Aptamers as Potential Therapeutics through Binding to the Different Forms of uPA.
    Dreymann N; Wuensche J; Sabrowski W; Moeller A; Czepluch D; Vu Van D; Fuessel S; Menger MM
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RAID3--An interleukin-6 receptor-binding aptamer with post-selective modification-resistant affinity.
    Mittelberger F; Meyer C; Waetzig GH; Zacharias M; Valentini E; Svergun DI; Berg K; Lorenzen I; Grötzinger J; Rose-John S; Hahn U
    RNA Biol; 2015; 12(9):1043-53. PubMed ID: 26383776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation.
    Tarui T; Akakura N; Majumdar M; Andronicos N; Takagi J; Mazar AP; Bdeir K; Kuo A; Yarovoi SV; Cines DB; Takada Y
    Thromb Haemost; 2006 Mar; 95(3):524-34. PubMed ID: 16525582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterisation of aptamer-target interactions by branched selection and high-throughput sequencing of SELEX pools.
    Dupont DM; Larsen N; Jensen JK; Andreasen PA; Kjems J
    Nucleic Acids Res; 2015 Dec; 43(21):e139. PubMed ID: 26163061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural investigations of recombinant urokinase growth factor-like domain.
    Beloglazova IB; Beabealashvilli RSh; Gursky YG; Bocharov EV; Mineev KS; Parfenova EV; Tkachuk VA
    Biochemistry (Mosc); 2013 May; 78(5):517-30. PubMed ID: 23848154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ab initio molecular orbital calculations on specific interactions between urokinase-type plasminogen activator and its receptor.
    Nagase K; Kobayashi H; Yoshikawa E; Kurita N
    J Mol Graph Model; 2009 Aug; 28(1):46-53. PubMed ID: 19403319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Building a Molecular Trap for a Serine Protease from Aptamer and Peptide Modules.
    Dupont DM; Bjerregaard N; Verpaalen B; Andreasen PA; Jensen JK
    Bioconjug Chem; 2016 Apr; 27(4):918-26. PubMed ID: 26926041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue-type plasminogen activator-binding RNA aptamers inhibiting low-density lipoprotein receptor family-mediated internalisation.
    Bjerregaard N; Bøtkjær KA; Helsen N; Andreasen PA; Dupont DM
    Thromb Haemost; 2015 Jul; 114(1):139-49. PubMed ID: 25855589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electroanalysis of pM-levels of urokinase plasminogen activator in serum by phosphorothioated RNA aptamer.
    Jarczewska M; Kékedy-Nagy L; Nielsen JS; Campos R; Kjems J; Malinowska E; Ferapontova EE
    Analyst; 2015 Jun; 140(11):3794-802. PubMed ID: 25620243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The construction and expression of chimeric urokinase-type plasminogen activator genes containing kringle domains of human plasminogen.
    Boutaud A; Castellino FJ
    Arch Biochem Biophys; 1993 Jun; 303(2):222-30. PubMed ID: 8512311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Facile characterization of aptamer kinetic and equilibrium binding properties using surface plasmon resonance.
    Chang AL; McKeague M; Smolke CD
    Methods Enzymol; 2014; 549():451-66. PubMed ID: 25432760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of amino-acid mutations on specific interactions between urokinase-type plasminogen activator and its receptor: Ab initio molecular orbital calculations.
    Tsuji S; Kasumi T; Nagase K; Yoshikawa E; Kobayashi H; Kurita N
    J Mol Graph Model; 2011 Aug; 29(8):975-84. PubMed ID: 21605990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracellular Expression of PAI-1 Specific Aptamers Alters Breast Cancer Cell Migration, Invasion and Angiogenesis.
    Fortenberry YM; Brandal SM; Carpentier G; Hemani M; Pathak AP
    PLoS One; 2016; 11(10):e0164288. PubMed ID: 27755560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.